AVX-001 | CAS#300553-18-8 | cytosolic phospholipase A2 inhibitor

MedKoo Cat#: 529703 | Name: AVX-001

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AVX-001 is a cytosolic phospholipase A2 (cPLA2) inhibitor potentially for the treatment of psoriasis.

Chemical Structure

AVX-001

CAS#300553-18-8

Theoretical Analysis

MedKoo Cat#: 529703

Name: AVX-001

CAS#: 300553-18-8

Chemical Formula: C21H29F3OS

Exact Mass: 386.1891

Molecular Weight: 386.51

Elemental Analysis: C, 65.26; H, 7.56; F, 14.75; O, 4.14; S, 8.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

AVX-001; AKH-217; FP-025; AVX001; AKH217; FP025; AVX 001; AKH 217; FP 025;

IUPAC/Chemical Name

1,1,1-trifluoro-3-(((2E,6Z,9Z,12Z,15Z)-octadeca-2,6,9,12,15-pentaen-1-yl)thio)propan-2-one

InChi Key

RBPYIYOPSGHFQG-IIFHDYRKSA-N

InChi Code

InChI=1S/C21H29F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-20(25)21(22,23)24/h3-4,6-7,9-10,12-13,16-17H,2,5,8,11,14-15,18-19H2,1H3/b4-3-,7-6-,10-9-,13-12-,17-16+

SMILES Code

O=C(CSC/C=C/CC/C=C\C/C=C\C/C=C\C/C=C\CC)C(F)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 386.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 Jan 20. doi: 10.1111/jdv.14128. [Epub ahead of print] PubMed PMID: 28107559. 2: Huwiler A, Feuerherm AJ, Sakem B, Pastukhov O, Filipenko I, Nguyen T, Johansen B. The ω3-polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A(2) and suppress PGE(2) formation in mesangial cells. Br J Pharmacol. 2012 Dec;167(8):1691-701. doi: 10.1111/j.1476-5381.2012.02114.x. PubMed PMID: 22831644; PubMed Central PMCID: PMC3525871.